Embolotherapy Market to Advance at an 8% CAGR in Coming Years

Embolotherapy Market to Advance at an 8% CAGR in Coming Years
Embolotherapy market in North America is expected to hold around 40% share by 2024. This can be mainly attributed to the rising cases of chronic diseases and increasing geriatric population.

In 2018, the global embolotherapy market generated a revenue of $3.0 billion and is expected to attain $4.8 billion by 2024, advancing at an 8.0% CAGR during the forecast period (2019–2024). In terms of product, embolic agents are projected to account for the larger share of the market and register the faster growth during the forecast period. The reason for this is the rising adoption of these agents for several interventional radiology procedures.

On the basis of procedure, transcatheter arterial embolization (TAE) is predicted to advance at the fastest pace in the embolotherapy market during the forecast period. This is because the TAE procedure has better toxicity profile as compared to other procedures, namely transarterial radioembolization/selective internal radiation therapy and transarterial chemoembolization. When indication is taken into consideration, cancer accounted for the major share of the market in 2018 due to the rising number of cases, especially liver and kidney cancers.

Request for sample copy of this report: https://www.psmarketresearch.com/market-analysis/embolotherapy-market/report-sample

A key factor contributing to the growth of the embolotherapy market is the rising patient pool. The increasing adoption of embolic procedures for managing several diseases is occurring due to the growing patient pool and surging healthcare spending. Moreover, the patients diagnosed at advanced and intermediate stages do not respond to curative therapies, including liver transplantation, ablation, and surgical reaction. Hence, the surging pool of patients, who are at an advanced stage of different life-threatening diseases, need embolotherapy intervention, which is resulting in the growth of the market. 

Geographically, North America is predicted of account for approximately 40.0% of the embolotherapy market in 2024 due to the increasing cases of chronic diseases and surging geriatric population. In the U.S., the population aged 65 years and above is predicted to increase to about 24% (98 million) by 2060 from 15% (46 million) in 2016. Other regions, including Asia-Pacific (APAC), Latin America (LATAM), Europe, and Middle East and Africa (MEA), are also expected to hold considerable shares of the market because of the increasing prevalence of cancer and neurological and peripheral vascular diseases in the regions.

Browse full report at: https://www.psmarketresearch.com/market-analysis/embolotherapy-market

The players operating in the embolotherapy market are launching different products in order to increase their shares. For example, Medtronic Plc launched Concerto 3D detachable coil system in Ireland and OptiSphere embolization spheres in the U.S. Some of the key players in the market are Terumo Corporation, Stryker Corporation, Sirtex Medical Limited, Meril Life Sciences Pvt. Ltd., Merit Medical Systems, Kaneka Corporation, Cook Medical Inc., Johnson & Johnson, Boston Scientific Corporation, Balt Extrusion, BTG Plc, Acandis GmbH, and Medtronic Plc.

Browse More Report by P&S Intelligence

Dermacosmetics Market

The dermacosmetics market is growing due to the rising number of dermacosmetics conferences, increasing inclination toward spending on appearance, rising prevalence of skin diseases, and growing purchasing power of consumers. Cosmetic products that are used by skincare specialists and dermatologists for the management of skin and hair disorders are termed as dermacosmetics.



Anatomic Pathology Market

The anatomic pathology market is observing the trend of the increasing adoption of new technologies, such as biobanking. It is the collection of samples of bodily tissues and fluids for the purpose of carrying out research for better understanding of diseases and health. In today’s time, when the emphasis is on obtaining faster test results for making a quick diagnosis, biobanking processes are being digitized for the easy storage and reference of test results. Additionally, the development of the liquid biopsy technique, coupled with next-generation sequencing, is revolutionizing the cancer diagnosis domain.


Media Contact
Company Name: P&S Intelligence
Contact Person: Abhishek
Email: Send Email
Phone: +918887787886
City: New York
Country: United States
Website: https://www.psmarketresearch.com/market-analysis/embolotherapy-market